{"entity":{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","aka":[],"tldr":"Immunologist who showed T cells recognise cancer neoantigens, the basis for personalised vaccines and TCR therapies.","summary":"Ton Schumacher is Senior Group Leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Leiden University. His specialisms are T-cell immunology, neoantigens and TCR discovery. His work demonstrated neoantigen-specific T-cell responses in melanoma patients, showing that T cells recognise cancer neoantigens, and he developed technologies for TCR discovery. His Science review on neoantigens in cancer immunotherapy set out the basis for personalised neoantigen vaccines and TCR-T cell therapies. He co-founded Neogene Therapeutics, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schumacher%20TN%5BAuthor%5D%20neoantigen"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["tcr-t","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Group Leader, Netherlands Cancer Institute; Professor, Leiden University","institutionId":"nki","specialisms":["T-cell immunology","Neoantigens","TCR discovery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schumacher%20TN%5BAuthor%5D%20neoantigen"}],"papers":[{"title":"Neoantigens in cancer immunotherapy","journal":"Science","year":2015,"doi":"10.1126/science.aaa4971"},{"title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2400634","doi":"10.1056/NEJMoa2400634"},{"title":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICHE-2%20neoadjuvant%20nivolumab%20ipilimumab%20dMMR%20colon%20cancer%20Chalabi%20NEJM%202024"},{"title":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2210233","doi":"10.1056/NEJMoa2210233"}],"orcid":"0000-0003-0517-8804"},"route":"/people/ton-schumacher/","neighbours":{"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"institution":[{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/"},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"term":[{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"}],"idea":[{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/"},{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/"}],"paper":[{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/"},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/"}]}}